Application deadline: August 10th, 2017 - APPLY HERE
Apply now if you are interested in meeting one-on-one with Forbion Capital Partners, after their "Investor Spotlight" presentation at JLabs on September 6th, 2017.
Advanced Code injection
Application deadline: August 10th, 2017 - APPLY HERE
Apply now if you are interested in meeting one-on-one with Forbion Capital Partners, after their "Investor Spotlight" presentation at JLabs on September 6th, 2017.
Application deadline: July 26, 2017 at 2:00pm EDT - APPLY HERE
One month left until the application deadline for the Postdoctoral Scholars 2017 program.
Please share this message with all current postdoctoral researchers at your institution.
NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ) the leading provider of proven comprehensive fluorescence imaging solutions that improve clinical outcomes and reduce healthcare costs in minimally invasive and open surgeries, today announced that it has entered into a definitive arrangement with Stryker Corporation to acquire all of the issued and outstanding shares of NOVADAQ.
TORONTO, June 6, 2017 ‐ Lumira Capital, a leading North American healthcare venture capital firm, announced today that it has launched a new philanthropic initiative whereby the firm’s partners will donate a portion of their profit share from Lumira Capital IV L.P. to up to fifteen leading healthcare foundations in Canada.
Are you a High Potential Canadian ICT or Life Science SME ready to grow in the US Boston Market? We can help.
CTA@Boston is an award-winning program that connects Canadian ICT and Life Science companies to US clients, strategic partners and investors, emphasizing aggressive business development and growth.
The Canadian Technology Accelerator in Boston (CTA@Boston) is looking for fast growing ICT and Life Science candidates for the Fall 2017 cohort.
Application Deadline: June 12, 2017
Formation Biologics, a clinical stage biopharmaceutical company, today announces the start of a multi-center, Phase I/IIa trial evaluating AVID100 in patients with epidermal growth factor receptor (EGFR)-expressing malignancies. The trial commenced at South Texas Accelerated Research Therapeutics in San Antonio, Texas.
OBIO CAAP 2016 company, Swift Medical, a market leader in machine vision and machine learning platforms for mobile health and data analytics, today announced completing a rounds of funding led by Montreal's Real Ventures with participation from Relay Ventures, Lumira Capital, MaRS IAF and a strategic partner.